Medscape
www.medscape.com

Biologic Therapies in Oncology 
Expert Column - Current and Emerging Targeted Therapies in the Treatment of Advanced Non-Small-Cell Lung Cancer
A couple of targeted therapies have already shown benefit in patients with NSCLC, with more on the horizon. Dr. Howard West examines the potential among a number of anti-EGFR and antiangiogenic agents.

Conference Report - Biologic Therapy Highlights of the American Society of Clinical Oncology 2006 Annual Meeting
The 2006 ASCO meeting featured promising findings among tyrosine kinase inhibitors, mTOR inhibitors, and EGFR inhibitors across a number of tumor types, including renal cell, colorectal, and breast cancers.

Journal Scan - The Latest Findings in Biologic Therapies
This literature review focuses on intriguing novel agents in the treatment of myelodysplastic syndromes, NSCLC, and advanced ovarian cancer.

Expert Column - Antiangiogenic Therapy in Colorectal Cancer: Managing Side Effects
Drs. David Cunningham and Yu Jo Chua review the latest understanding in the risk of side effects with antiangiogenic therapy, and discuss ways to manage these risks.

Conference Report - Highlights in Targeted Therapy at the 31st European Society of Medical Oncology Congress
In this report from ESMO 2006, Dr. Ezra Cohen highlights advances in targeted therapies for breast, renal cell, and non-small-cell lung cancers.

Journal Scan - The Latest Findings in Biologic Therapies
Dr. David Spigel reviews major findings published recently in the use of targeted therapies for breast, renal cell, and non-small-cell lung cancers.